Laborkontrollen vor, während und nach einer Thrombolysetherapie im Kindesalter

Zusammenfassung

Thrombosen im Kindes- und Jugendalter sind ernst zu nehmende Ereignisse und erfordern neben einer Ursachenklärung eine adäquate Therapie. Bei den heute üblichen Lysetherapien im Kindesalter haben Laboranalysen neben der Überwachung der Antikoagulanzientherapie die wesentliche Aufgabe der Therapiesteuerung. Die Laboranalyse besteht vor Thrombolysetherapie in der Bestimmung von Thrombozytenzahl, Hämoglobin, TPZ, aPTT, Fibrinogen, Antithrombin, Plasminogen und D-Dimer. Während der Lysetherapie sollen zur Therapiesteuerung, zur Erfassung von möglichen Nebenwirkungen und Begleitantikoagulation Thrombozyten, Hämoglobin, aPTT, Antithrombin, Plasminogen und D-Dimer bestimmt werden. Zur Verhinderung einer Reokklusion unter voller Antikoagulation nach Thrombolyse besteht die Laborkontrolle in der Akutphase in der Analyse von aPTT, Antithrombin und D-Dimer.

Schlüsselwörter

Thrombolyse - Laborkontrolle - Kindesalter

• LITERATUR

• 1 Andrew M. Developmental hemostasis: relevance to thromboembolic complications in pediatric patients. Thromb Haemost 1995; 74: 415-25.
• 2 Andrew M, David M, Adams M. Venous thromboembolic complications in children. J Pediatr 1993; 123: 337-46.
• 3 Andrew M, Marzinotto V, Massicotte P. et al. Heparin therapy in pediatric patients: a prospective cohort study. Ped Res 1994; 35: 78-83.
• 4 Andrew M, Paes B, Milner R, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 1990; 12: 95-104.
• 5 Andrew M, Vegh P, Johnston M. et al. Maturation of the hemostatic system during childhood. Blood 1992; 80: 1998-2005.
• 6 Bounameaux H, Cirafici P, Dermoueloose P. Measurement of D-Dimer in plasma as diagnostic aid in suspected pulmonary embolism. Lancet 1991; 337: 196-200.
• 7 Conard J, Samama MM. Theoretic and practical considerations on laboratory monitoring of thrombolytic therapy. Sem Thromb Haemost 1987; 13: 212-22.
• 8 Corrigan JJ. Neonatal thrombosis and the thrombolytic system: pathophysiology and therapy. Am J Pediatr Hematol Oncol 1988; 10: 83-91.
• 9 Dahlbäck B. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg 506 to Gin mutation in factor V as a pathogenetic risk factor. Thromb Haemost 1995; 74: 139-48.
• 10 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Aca Sci USA 1993; 90: 1004-8.
• 11 David M, Andrew M. Venous thromboembolic complications in children. J Pediatr 1993; 123: 337-46.
• 12 David M, Manco-Johnson M, Andrew M. Diagnosis and treatment of venous thromboembolism in children and adolescents. On behalf of the subcommittee on perinatal haemostasis of the scientific and standardization committee of the ISTH. Thromb Heamost 1995; 74: 791-2.
• 13 Egbring R, Seitz R, Behling T, Betke C. Die Prophylaxe von Infarktgefäßen nach intrakoronarer Thrombolyse: Einfluß von Antithrombin III?. Hämostaseologie 1989; 9: 3-7.
• 14 Göbel U. Inherited or acquired disorders of blood coagulation in children with neurovascular complications. Neuropediatrics 1994; 25: 4-7.
• 15 Hoffmann JJML, Vijgen M, Nieuwenhuizen W. Comparison of the specificity of 4 fibrinogen assays during thrombolytic therapy. Fibrinolysis 1990; 4 S2 121-3.
• 16 Kohlhase B, Vielhaber H, Kehl HG. et al. Thromboembolism and resistance to activated protein C (APCR) in children with underlying cardiac disease. J Pediatr 1996 (in press)
• 17 van Kuijck MAP, Rotteveel JJ, van Oostrom CG, Novakova I. Neurological complications in children with protein C deficiency. Neuropediatrics 1993; 25: 16-9.
• 18 Lojewski B, Bacher P, Iqbal O. et al. Evaluation of hemostatic and fibrinolytic alterations associated with daily administration of low-molecular-weight heparin for a 12-week period. Sem Thromb Haemost 1995; 21: 228-39.
• 19 Mannucci PM, Tripodi A. Laboratory screening of inherited thrombotic syndromes. Thromb Haemost 1987; 57: 247-51.
• 20 Nowak-Göttl U, Ashka I, Koch HG. et al. Resistance to activated protein C (APCR) in children with acute lymphoblastic leukaemia - the need for a prospective multicentre study. Blood Coagulation & Fibrinolysis 1995; 6: 761-4.
• 21 Nowak-Göttl U, Koch HG, Aschka I. et al. Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism. Br J Haematol 1996; 92: 992-8.
• 22 Nuss R, Hys T, Manco-Johnson M. Childhood thrombosis. Pediatrics 1995; 96: 291-4.
• 23 Massicotte P, Adams M, Marzinotto V. et al. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 128 313-8
• 24 Petäjä J, Jalanko H, Holmberg C. et al. Resistance to activated protein C as an underlying cause of recurrent venous thrombosis during relapsing nephrotic syndrome. J Pediatr 1995; 127: 103-5.
• 25 Ring ME, Butman SM, Bruck DC. et al. Fibrin metabolism in patients with acute myocardial infarction during and after treatment with tissue-type plasminogen activator. Thromb Haemost 1988; 60: 428-33.
• 26 Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics 1995; 96: 939-43.
• 27 Shen L, Dahlbäck B. Factor V and protein C in degradation of factor Villa. J Biol Chem 1994; 269: 18735-8.
• 28 Siegbahn A, Ruusuvaara L. Age dependence of blood fibrinolytic components and the effects of lowe-dose oral anticoagulants on coagulation and fibrinolysis in teenagers. Thromb Haemost 1988; 60: 361-4.
• 29 Simioni P, Girolami A. Homozygous factor V - deficient patients show resistance to activated protein C whereas heterozygotes do not. Blood Coagulation & Fibrinolysis 1994; 5: 825-7.
• 30 Simioni P, De Ronde H, Prandoni P. et al. Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds. Stroke 1995; 26: 885-90.
• 31 Vielhaber H, Kohlhase B, Kehl HG. et al. Flush heparin during cardiac catherisation prevents long-term coagulation activation in children without APC-Resistance-preli-minary results. Thromb Res 1996; 81: 651-6.
• 32 Zenz W, Muntean W, Gallistl S. et al. Inherited resistance to activated protein C in a boy with multiple thromboses in early infancy. Eur J Pediatr 1994; 154: 285-8.